Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 2 bp deletion in exon7 and 370 bp deletion in exon7.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-EHMT2, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
EHMT2 also known as G9a is a methyltransferase enzyme with a molecular mass of approximately 165 kDa. It modifies histones by adding methyl groups to lysine 9 on histone H3 which results in chromatin structure changes and influences gene expression. EHMT2/G9a expresses in various tissues including brain heart and liver showing its widespread role in different physiological processes. As a well-studied protein researchers often analyze EHMT2 activity using assays like ELISA and western blot.
Biological function summary
EHMT2/G9a regulates gene expression by altering chromatin accessibility. It is part of a chromatin remodeling complex interacting with proteins such as ANMTA02. Through its methyltransferase activity it maintains an epigenetic silence state important for embryonic development differentiation and cellular identity. EHMT2/G9a plays a significant role in the repression of transcriptional activity of tumor suppressor genes and developmental genes.
Pathways
G9a functions in epigenetic signaling pathways and influences processes like the cell cycle and DNA damage repair. It interacts with proteins in the Polycomb repressive complex such as EZH2 to regulate gene silencing. Additionally in the DNA damage response pathway G9a can associate with histone deacetylases to stabilize chromatin and prevent unwarranted gene expression.
Aberrant regulation of EHMT2/G9a associates with cancer and neurodevelopmental disorders. In various cancers such as leukemia G9a suppresses tumor suppressor genes aiding tumor progression. Connections between G9a and proteins like DNMT1 highlight its role in maintaining a hypermethylation state in cancerous cells. In neurodevelopmental disorders altered expression of G9a affects synaptic plasticity linking it with cognitive impairments and autism spectrum disorders.
